Through our relentless dedication, we have emerged as frontrunners in the fields of oncology, hematology, transplant cases, and rare diseases. Since 2004, we have proudly partnered with over 15 international companies and extended our reach to several other Latin American nations.
Our primary focus is on developing and manufacturing high-quality pharmaceuticals, driven by an unwavering commitment to optimizing patient care. Our distinguished reputation stems from long-standing collaborations with the medical and scientific communities, where we prioritize innovation and continuous improvement in line with rigorous international quality standards.
registered
products worldwide
products in
Latin America
Participated in Buenos Aires from May 7 to 10, connecting with the medical community and focusing on the benefits of Bocipal (Relugolix 40 mg).
A premier global event on April 25 and 26 at the Punta del Este Convention & Exhibition Center, focusing on the latest updates in hematology.
Participated in one of the world's most significant urology congresses from April 26 to 29 in Las Vegas, Nevada.
Varifarma Symposium: "Clinical Experience with GORAX (Relugolix 120 mg) in Advanced Prostate Cancer" at SAU Conference from April 10 to 11.
Present at the “Daily Hematology” Conference in Montevideo from March 12 to 14.
Confidence in the control of complex fungal infections.
Discover our participation in the event we joined alongside the Uruguayan Society of Medical and Pediatric Oncology.
We are expanding our portfolio with another product for breast cancer treatment.
24th Lymphoma, Leukemia, and Myeloma Congress: the ideal scenario to reaffirm our commitment.
Leading the pharmaceutical industry into the future.
We had the pleasure of attending the Hematology Update Conference on October 1st.
A record-breaking congress with the latest innovations.
Setting a new standard of care in advanced prostate cancer treatment.
